Date:2/23/2010

c $(0.09) $(0.53) $ 0.27 $ 0.03 ======= ======== ======= ====== Diluted (2) $(0.09) $(0.53) $ 0.27 $ 0.03 ======= ======== ======= ====== Shares used in computing net income (loss) per share: Basic 62,189 56,430 59,215 55,915 ======= ======== ======= ====== Diluted (2) 62,189 56,430 59,507 56,765 ======= ======== ======= ====== (1) Includes employee stock-based compensation charges of: Research and development $1,288 $1,083 $3,574 $3,166 Selling, general, and administrative 4,858 3,904 17,506 15,630 ------ ------ ------- ------- Total employee stock-based compensation $6,146 $4,987 $21,080 $18,796 ======= ======== ======= ======= (2) Computation of net income (loss) used in computing diluted per share amounts: Net income (loss) $(5,509) $(30,187) $16,161 $1,948 Add: Interest and issuance costs related to dilutive convertible senior notes (3) - - - - ------ ------ ------- ------- Net income (loss) used in computing diluted per share amounts $(5,509) $(30,187) $16,161 $1,948 ======= ========
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
Related medicine technology :

1. Poniard Pharmaceuticals Secures $20 Million Committed Equity Financing Facility
2. Jazz Pharmaceuticals to Announce Fourth Quarter and Full Year 2009 Financial Results on March 3, 2010
3. Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010
4. Jiangbo Pharmaceuticals Announces Conference Call to Discuss Results for Its Second Quarter of Fiscal Year 2010
5. Adamas Pharmaceuticals Announces In Vitro Data Demonstrating TCAD Therapy is More Potent Than Double Combinations or Monotherapy Against Drug-Resistant Flu Strains
6. Ritter Pharmaceuticals Joins NIH Conference Discussions on Lactose Intolerance and Associated Health Risks
7. Endo Pharmaceuticals Reports Strong Fourth Quarter and Full-Year 2009 Financial Results: Provides 2010 Financial Guidance
8. Alexza Pharmaceuticals Promotes Mark K. Oki to Vice President, Finance and Controller
9. Jazz Pharmaceuticals Announces FDA Acceptance of its New Drug Application for JZP-6 (sodium oxybate) for the Treatment of Fibromyalgia
10. Transdel Pharmaceuticals Announces Management Reorganization
11. Merz Pharmaceuticals Introduces New Mederma(R) Stretch Marks Therapy Now Available in Drugstores Nationwide